Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Testing effectiveness (Phase 2)Ended earlyNCT04720664
What this trial is testing

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor Positive Breast Carcinoma
Georgetown University 11
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Testing effectiveness (Phase 2)UnknownNCT05025735
What this trial is testing

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-negative Breast Cancer
Saint Luke's Health System 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04448886
What this trial is testing

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Who this might be right for
Invasive Breast CancerMetastatic Breast CancerHR-Positive Breast Cancer+1 more
Ana C Garrido-Castro, MD 110
Early research (Phase 1)UnknownNCT05337657
What this trial is testing

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Genor Biopharma Co., Ltd. 10
Early research (Phase 1)Looking for participantsNCT06678269
What this trial is testing

Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerStage IV Breast CancerBreast Cancer+5 more
Memorial Sloan Kettering Cancer Center 28
Not applicableStudy completedNCT07561346
What this trial is testing

Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

Who this might be right for
HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
Hellenic Cooperative Oncology Group 3,648
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT06276868
What this trial is testing

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Henan Cancer Hospital 71
Large-scale testing (Phase 3)Active Not RecruitingNCT05346224
What this trial is testing

Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer
Shanghai Henlius Biotech 900
Testing effectiveness (Phase 2)Study completedNCT04796623
What this trial is testing

TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 122
Testing effectiveness (Phase 2)Looking for participantsNCT06705127
What this trial is testing

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Who this might be right for
HR-positive,HER2-negative Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06950086
What this trial is testing

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

Who this might be right for
HR-positive, HER2-negative Advanced Breast Cancer
TYK Medicines, Inc 180
Testing effectiveness (Phase 2)Study completedNCT03555877
What this trial is testing

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer Metastatic
GBG Forschungs GmbH 56
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Not applicableNot Yet RecruitingNCT07521202
What this trial is testing

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Who this might be right for
HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit 257
Early research (Phase 1)UnknownNCT06172322
What this trial is testing

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Who this might be right for
HR Positive/HER-2 Negative Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 42
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Next Page